{
  "docId": "019dd923-622c-750b-8b97-6463cf2ae738",
  "docSlug": "be088263ccbf",
  "documentTitle": "Chinook Therapeutics Inc (KDNY)",
  "authorId": "51_Muddy_Waters",
  "authorName": "Carson C. Block",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-06-07 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 4,
  "pageCount": 10,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "This is a text-heavy research note page focusing on accounting irregularities and investor behavior.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-6463cf2ae738/4",
  "deckHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-6463cf2ae738#slide-4",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Chinook, in our opinion, improperly recorded collaboration and licensing revenues from SanReno in 2021 and 2022. This seems to have been an intentional mischaracterization to create the false impression that Chinook’s pipeline, especially atrasentan, can be easily monetized and generate repeatable and sustainable revenue.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2b61-7647-86f5-5657d9e9351a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.78,
        "x": 0.11,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "Chinook, in our opinion, improperly recorded collaboration and licensing revenues from SanReno in 2021 and 2022. This seems to have been an intentional mischaracterization to create the false impression that Chinook’s pipeline... can be easily monetized.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f091250-36fe-4349-b983-714e297415b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "For example, the financial impact of the revenue streams from SanReno JV was described potentially “very significant” in the 2022 JPM Healthcare conference (Jan 4 2022). — Chinook 2023 corporate presentation, Slide 25",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2b61-7647-86f5-5a01c5e6afd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.78,
        "x": 0.11,
        "y": 0.71
      },
      "kind": "source-note",
      "text": "Footnotes 21-32 detailing sources including S&P Capital IQ, 10-K filings, and Muddy Waters research.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3d5c0b1-8152-481b-9f98-596ec934b670",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "05f9734c-888a-4446-817e-c1dc7f80d37c",
      "evidence": "The text explicitly argues that Chinook 'improperly recorded' revenue to create a 'false impression' of sustainability.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "a3326d1b-6ad9-4abf-8bef-7e903a59a20f",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "Chinook Therapeutics: Too Little, Too Late; Collaboration and License Revenue",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 2,
      "name": "The Reveal",
      "slug": "05-the-reveal",
      "bestFor": "Product launches, strategic pivots, unexpected findings",
      "matchId": "009545be-21ff-414e-af6c-ab96f9e3c507",
      "evidence": "Comparison of reported and adjusted revenue",
      "position": 0,
      "objective": "Reveal the true financial performance of Chinook Therapeutics",
      "structure": "Setup the Question -> Build Suspense -> The Big Reveal",
      "confidence": 0.7,
      "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion"
    },
    {
      "to": 10,
      "from": 2,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6849d576-3f2a-4af6-a2ad-5069a2d1b999",
      "evidence": "Implications for investors",
      "position": 1,
      "objective": "Highlight the risks of not addressing accounting practices",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}